All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

1,397

2012 to 2026

Breakthrough

234

Accelerated

121

Priority review

759

Orphan

1397

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
2012254
2013246
20143715
20154117
20163920
20177426
20188842
20197426
20207947
20216730
20226727
20237741
20248452
202510163
20266044

1,397 approvals

Newest first. Hover a badge for what it means.

  • Klygefa (Gefurulimab) · Alexion PharmNov 13, 2026
    Original approval · BLA 761488NovelOrphan

    To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

  • Myqorzo (Aficamten) · CytokineticsNov 13, 2026
    Efficacy supplement 2 · NDA 219083Orphan
  • Skyrizi (Risankizumab-Rzaa) · Abbvie INCOct 23, 2026
    Efficacy supplement 53 · BLA 761105Priority reviewOrphanApproval letter
  • Ultomiris (Ravulizumab-Cwvz) · Alexion PharmOct 21, 2026
    Efficacy supplement 46 · BLA 761108Priority reviewOrphanApproval letter
  • Ayvakit (Avapritinib) · Blueprint MedicinesOct 16, 2026
    Efficacy supplement 21 · NDA 212608OrphanApproval letter
  • Keytruda (Pembrolizumab) · Merck Sharp DohmeOct 16, 2026
    Efficacy supplement 191 · BLA 125514OrphanApproval letter
  • Zilbrysq (Zilucoplan Sodium) · Ucb INCOct 15, 2026
    Efficacy supplement 15 · NDA 216834OrphanApproval letter
  • Repatha (Evolocumab) · Amgen INCOct 9, 2026
    Efficacy supplement 47 · BLA 125522OrphanApproval letter
  • Tukysa (Tucatinib) · SeagenOct 7, 2026
    Efficacy supplement 10 · NDA 213411OrphanApproval letter
  • Jaypirca (Pirtobrutinib) · Loxo OncolOct 2, 2026
    Efficacy supplement 6 · NDA 216059OrphanApproval letter
  • Camzyos (Mavacamten) · BristolSep 30, 2026
    Efficacy supplement 13 · NDA 214998Priority reviewOrphanApproval letter
  • Emcitate (Tiratricol) · Rare ThyroidSep 28, 2026
    Original approval · NDA 220963NovelPriority reviewOrphanApproval letter

    To treat peripheral thyrotoxicosis in patients with MCT8 deficiency

  • Atebrioz (Zilurgisertib Fumarate) · MirumSep 25, 2026
    Original approval · NDA 221198NovelPriority reviewOrphanApproval letter

    To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva

  • Gazyva (Obinutuzumab) · GenentechSep 25, 2026
    Efficacy supplement 43 · BLA 125486Priority reviewOrphanApproval letter
  • Lenvima (Lenvatinib Mesylate) · Eisai INCSep 24, 2026
    Efficacy supplement 35 · NDA 206947OrphanApproval letter
  • Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
    Original approval · NDA 220425NovelPriority reviewOrphanApproval letter

    To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement

  • Winrevair (Sotatercept-Csrk) · Merck Sharp DohmeSep 21, 2026
    Efficacy supplement 12 · BLA 761363OrphanApproval letter
  • Aqneursa (Levacetylleucine) · IntrabioSep 18, 2026
    Efficacy supplement 2 · NDA 219132Priority reviewOrphanApproval letter
  • Ibtrozi (Taletrectinib Adipate) · NuvationSep 16, 2026
    Efficacy supplement 4 · NDA 219713OrphanApproval letter
  • Tagrisso (Osimertinib Mesylate) · AstrazenecaSep 14, 2026
    Efficacy supplement 35 · NDA 208065OrphanApproval letter
  • Isembyld (Apitegromab-Mstn) · Scholar Rock INCSep 11, 2026
    Original approval · BLA 761463NovelPriority reviewOrphanApproval letter

    To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment

  • Joenja (Leniolisib Phosphate) · PharmingSep 11, 2026
    Efficacy supplement 6 · NDA 217759Priority reviewOrphanApproval letter
  • Pixclara (Floretyrosine F-18) · TelixSep 11, 2026
    Original approval · NDA 218592NovelPriority reviewOrphanApproval letter

    To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations

  • Hyrnuo (Sevabertinib) · Bayer HealthcareSep 9, 2026
    Efficacy supplement 1 · NDA 219972Priority reviewOrphanApproval letter
  • Zanvastro (Zilganersen Sodium) · Ionis Pharms INCSep 3, 2026
    Original approval · NDA 220210NovelPriority reviewOrphanApproval letter

    To treat Alexander disease in pediatric and adult patients

  • Stelara (Ustekinumab) · Janssen BiotechAug 28, 2026
    Efficacy supplement 21 · BLA 761044OrphanApproval letter
  • Mimrylo (Rusfertide Acetate) · Takeda Pharms AmAug 28, 2026
    Original approval · NDA 220605NovelPriority reviewOrphanApproval letter

    To treat erythrocytosis in adults with polycythemia vera

  • Besremi (Ropeginterferon Alfa-2b-Njft) · Pharmaessentia CorpAug 28, 2026
    Efficacy supplement 13 · BLA 761166OrphanApproval letter
  • Lisraya (Brepocitinib Tosylate) · Priovant TherapAug 27, 2026
    Original approval · NDA 220106NovelPriority reviewOrphanApproval letter

    To treat dermatomyositis in adults

  • Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
    Original approval · NDA 220910NovelPriority reviewOrphanApproval letter

    To treat metastatic pancreatic cancer

  • Tevimbra (Tislelizumab-Jsgr) · BeigeneAug 25, 2026
    Efficacy supplement 18 · BLA 761232Priority reviewOrphanApproval letter
  • Ziihera (Zanidatamab-Hrii) · Jazz PharmsAug 25, 2026
    Efficacy supplement 2 · BLA 761416Priority reviewOrphanApproval letter
  • Imaavy (Nipocalimab-Aahu) · Janssen BiotechAug 24, 2026
    Efficacy supplement 2 · BLA 761430Priority reviewOrphanApproval letter
  • Empaveli (Pegcetacoplan) · Apellis PharmsAug 20, 2026
    Efficacy supplement 12 · NDA 215014OrphanApproval letter
  • Pasatru (Garetosmab-Grts) · Regeneron Pharmaceuticals, INCAug 19, 2026
    Original approval · BLA 761508NovelPriority reviewOrphanApproval letter

    To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva

  • Zenbexus (Iberdomide Hydrochloride) · Bristol Myers SquibbAug 13, 2026
    Original approval · NDA 221075NovelPriority reviewOrphanApproval letter

    To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent

  • Orzeyful (Oveporexton) · Takeda Pharms USAAug 5, 2026
    Original approval · NDA 220860NovelPriority reviewOrphanApproval letter

    To treat narcolepsy type 1

  • Zimrixby (Rituximab-Cdxx) · Dr Reddys Labs SAJul 31, 2026
    Original approval · BLA 761376OrphanApproval letter
  • Macrilen (Macimorelin Acetate) · Aeterna ZentarisJul 23, 2026
    Efficacy supplement 5 · NDA 205598Priority reviewOrphanApproval letter
  • Jideytro (Zidesamtinib) · NuvalentJul 22, 2026
    Original approval · NDA 220185NovelOrphanApproval letter

    To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor

  • Rezzayo (Rezafungin Acetate) · MundipharmaJul 16, 2026
    Efficacy supplement 7 · NDA 217417OrphanApproval letter
  • Retevmo (Selpercatinib) · Eli Lilly and COJul 14, 2026
    Efficacy supplement 17 · NDA 213246OrphanApproval letter
  • Retevmo (Selpercatinib) · Eli Lilly and COJul 14, 2026
    Efficacy supplement 7 · NDA 218160OrphanApproval letter
  • Sarclisa Escena (Isatuximab-Irfc) · Sanofi-Aventis U.S. LLCJul 9, 2026
    Original approval · BLA 761445OrphanApproval letter
  • Skyrizi (Risankizumab-Rzaa) · Abbvie INCJun 26, 2026
    Efficacy supplement 45 · BLA 761105OrphanApproval letter
  • Tryngolza (Autoinjector) (Olezarsen Sodium) · Ionis Pharms INCJun 24, 2026
    Efficacy supplement 4 · NDA 218614Breakthrough therapyPriority reviewOrphanApproval letter
  • Skyrizi (Risankizumab-Rzaa) · Abbvie INCJun 12, 2026
    Efficacy supplement 44 · BLA 761105OrphanApproval letter
  • Tzield (Teplizumab-Mzwv) · Provention Bio INCJun 12, 2026
    Efficacy supplement 10 · BLA 761183Priority reviewOrphanApproval letter
  • Ambelvist (Gadoquatrane) · Bayer HealthcareJun 12, 2026
    Original approval · NDA 219627NovelOrphanApproval letter

    To detect and visualize lesions with abnormal vascularity, in conjunction with MRI

  • Alecensa (Alectinib Hydrochloride) · Hoffmann-La RocheJun 11, 2026
    Efficacy supplement 16 · NDA 208434OrphanApproval letter
Page 1 of 28Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.